upadacitinibRinvoqPalmoplantar pustulosisNewcastle North Tyneside 2 Research Ethics CommitteeQuintet Recruitment InterventionJanus kinase (JAK) inhibitors
…(n=20) will receive 8 weeks of treatment with the JAK inhibitor upadacitinib (‘Rinvoq’, 30 mg, once daily). Qualitative semistructured inter…